NEW YORK (GenomeWeb) – Trovagene today announced an offering of 4 million shares of its common stock, which is expected to bring in gross proceeds of around $35 million.

The offering is expected to close on or about July 22. Trovagene has also granted the underwriters a 30-day option to purchase up to an additional 600,000 shares.

The firm said proceeds from the offering will fund research and development, serve as working capital, and support other general corporate purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.